2025 publications!

On

2025 has been a busy year for the lab on many fronts... including publications! Here is a summary of all the papers published this year that were lead by one of our fantastic lab members!

Recommendations and guidelines

  • Rabinovici et al, Alz&Dem and JNM. Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
  • Rabinovici et al, JPAD. Appropriate use recommendations for Donanemab
  • La Joie et al, Alz&Dem. Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies

Publications on LEADS study

  • Lagarde et al, Annals of Neurology (senior author: Gil Rabinovici). Comparison of Amyloid-PET measures in LEADS (Early Onset AD) versus ADNI (Late Onset AD)
  • Njamnshi et al, Alz&Dem (senior author: Renaud La Joie). Evaluation of Tablet based cognitive assessment (TabCAT) in LEADS, including associations with pen-and-paper tests, amyloid-PET positivity, and tau-PET patterns

Harmonization of Amyloid-PET measurements 

  • Soleimani-Meigooni et al, Al&Dem (senior author: Gil Rabinovici). Calibration of visual reads for 10 readers in the CLARiTI study using a multi-tracer dataset enriched in difficult scans.
  • Zhang et al, JNM (senior author: Ganna Blazhenets). Evaluation of the robustness of Centiloid calculation due to calibration dataset sample size and image resolution.

Publications on IDEAS/NEW IDEAS study

  • Zeltzer at al, JAMA Neurology (senior author: Renaud La Joie). Analysis of the concordance between amyloid-PET visual reads done in the clinic and centralized quantification of Centiloids in the IDEAS study (n=10,350 patients with MCI/dementia)
  • Abu Raya et al, Alz&Dem (senior author: Gil Rabinovici). Analysis of sex differences in amyloid-PET positivity and burden (in Centiloids) in the IDEAS study.
  • Windon et al, Alz&Dem (senior author: Gil Rabinovici). Description of the NEW IDEAS dataset and changes in management following amyloid-PET scans.

Tau-PET

  • Malpetti et al, AlzResTher (senior author: Gil Rabinovici). Associations between baseline tau-PET patterns and future decline in different cognitive domains in early clinical stages of AD
  • Alosco et al, Mol Neurodeg (senior author: Gil Rabinovici). Assessment of MK6240 in patients at risk for Chronic Traumatic Encephalopathy.

Literature reviews:

  • Wisse et al, Alz&Dem (senior author: Renaud La Joie). Review on the contribution of AD tau versus TDP43 (LATE) to Medial Temporal Atrophy in aging and AD.
  • Chiotis et al, JNM (senior author: Gil Rabinovici). Review on the role of amyloid- and tau-PET in the new era of AD therapies.